Intranasal Neural Stem Cell-Derived Extracellular Vesicles Reverse Hippocampal Neuroinflammaging and Mitigate Mitochondrial Decay
Researchers at Texas A&M have developed an intranasal therapy utilizing stem cell-derived extracellular vesicles to bypass the blood-brain barrier and deliver regulatory microRNA payloads directly to the hippocampus. This intervention downregulates the NLRP3 and cGAS-STING pathways, suppressing chronic microglial inflammation and restoring neuronal mitochondrial function in animal models.
Targeted Routing and Barrier Bypass
Direct therapeutic access to the central nervous system is restricted by the blood-brain barrier, which blocks most systemic drug delivery mechanisms. To bypass this physical barrier, researchers at the Texas A&M University Naresh K. Vashisht College of Medicine developed an intranasal delivery system using human neural stem cell-derived extracellular vesicles (EVs). These microscopic biological parcels serve as delivery vectors, transporting regulatory cargo directly into brain tissue through the nasal cavity.
Once absorbed, the EVs target the aging hippocampus. By employing an intranasal delivery route, the therapy achieves direct brain penetration, eliminating the need for invasive surgical procedures or complex drug delivery modifications. This approach enables the molecular cargo to interact directly with the brain's resident immune cells.
MicroRNA Payloads and Inflammatory Pathway Suppression
The active functional components of these EVs are microRNAs, which operate as master regulators to modulate gene expression and cell signaling networks. In the aging brain, chronic low-grade inflammation—termed neuroinflammaging—is driven by persistent immune activation within microglial cells, contributing to cognitive decline and elevating the risk of neurodegenerative disorders like Alzheimer's disease.
Upon uptake by target microglia, the delivered microRNAs selectively suppress inflammatory signaling architectures. The therapy specifically restrains the NLRP3 inflammasome and cGAS-STING signaling pathways, which are primary drivers of chronic inflammation in aged brains. Deactivating these pathways halts the microglial inflammatory cascade, restoring the cellular transcriptome to a stable state.
Mitochondrial Reactivation and Behavioral Performance
Beyond suppressing active inflammation, the therapy addresses cellular energy production by recharging neuronal mitochondria. Chronic neuroinflammaging correlates with elevated oxidative stress and mitochondrial decay, which starves neurons of necessary cellular energy. The microRNA payload mitigates this oxidative stress, allowing the brain's own repair systems to reactivate mitochondrial energy production.
- Enhanced recognition of familiar objects
- Improved detection of novel objects
- Faster adaptation to environmental changes
These cognitive and physiological improvements persisted for several months. The treatment outcomes were identical across both male and female subjects, representing a universal efficacy profile.
Systemic Implications and Patent Status
The research, led by Dr. Ashok Shetty, Dr. Madhu Leelavathi Narayana, and Dr. Maheedhar Kodali, was published in the Journal of Extracellular Vesicles under the title "Intranasal Human NSC-Derived EVs Therapy Can Restrain Inflammatory Microglial Transcriptome, and NLRP3 and cGAS-STING Signalling, in Aged Hippocampus." The project received funding and resource support from the National Institute on Aging (NIA).
To transition this technology from laboratory models to clinical applications, the Texas A&M research team has filed a U.S. patent for the therapy. The primary objective is to scale this non-invasive approach to replace complex, high-risk surgical interventions and long-term pharmacological protocols for age-related cognitive decline, stroke recovery, and dementia.